JP2019533672A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019533672A5 JP2019533672A5 JP2019519420A JP2019519420A JP2019533672A5 JP 2019533672 A5 JP2019533672 A5 JP 2019533672A5 JP 2019519420 A JP2019519420 A JP 2019519420A JP 2019519420 A JP2019519420 A JP 2019519420A JP 2019533672 A5 JP2019533672 A5 JP 2019533672A5
- Authority
- JP
- Japan
- Prior art keywords
- mini
- melatonin
- tablet
- controlled release
- effective amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008185 minitablet Substances 0.000 claims 50
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 claims 37
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 claims 37
- 229960003987 melatonin Drugs 0.000 claims 37
- 238000013270 controlled release Methods 0.000 claims 35
- 229920001577 copolymer Polymers 0.000 claims 9
- 239000003937 drug carrier Substances 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims 5
- XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 claims 5
- 235000019700 dicalcium phosphate Nutrition 0.000 claims 5
- 229960001021 lactose monohydrate Drugs 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- 238000000576 coating method Methods 0.000 claims 4
- 230000001939 inductive effect Effects 0.000 claims 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 4
- 239000003826 tablet Substances 0.000 claims 4
- 239000011248 coating agent Substances 0.000 claims 3
- 238000009472 formulation Methods 0.000 claims 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000037406 food intake Effects 0.000 claims 2
- 229960001375 lactose Drugs 0.000 claims 2
- 239000008101 lactose Substances 0.000 claims 2
- 241000282412 Homo Species 0.000 claims 1
- 230000036765 blood level Effects 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 230000027288 circadian rhythm Effects 0.000 claims 1
- 238000004090 dissolution Methods 0.000 claims 1
- 238000007580 dry-mixing Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000003278 mimic effect Effects 0.000 claims 1
- 239000008016 pharmaceutical coating Substances 0.000 claims 1
- 239000008024 pharmaceutical diluent Substances 0.000 claims 1
- 230000010363 phase shift Effects 0.000 claims 1
- 230000009747 swallowing Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662415014P | 2016-10-31 | 2016-10-31 | |
| US62/415,014 | 2016-10-31 | ||
| PCT/IB2016/057190 WO2018078429A1 (en) | 2016-10-31 | 2016-11-29 | Melatonin mini-tablets and method of manufacturing the same |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019533672A JP2019533672A (ja) | 2019-11-21 |
| JP2019533672A5 true JP2019533672A5 (OSRAM) | 2020-01-09 |
| JP6830156B2 JP6830156B2 (ja) | 2021-02-17 |
Family
ID=57482481
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019519420A Active JP6830156B2 (ja) | 2016-10-31 | 2016-11-29 | メラトニンミニタブレットおよびその製造方法 |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US10722494B2 (OSRAM) |
| EP (3) | EP3777842B1 (OSRAM) |
| JP (1) | JP6830156B2 (OSRAM) |
| KR (1) | KR102167190B1 (OSRAM) |
| CN (1) | CN109922795B (OSRAM) |
| AU (6) | AU2016426598C1 (OSRAM) |
| CA (1) | CA3040027C (OSRAM) |
| CY (1) | CY1123449T1 (OSRAM) |
| DK (2) | DK3777842T3 (OSRAM) |
| ES (2) | ES3009413T3 (OSRAM) |
| FI (1) | FI3777842T3 (OSRAM) |
| HR (2) | HRP20201722T1 (OSRAM) |
| HU (2) | HUE051362T2 (OSRAM) |
| IL (1) | IL262537B (OSRAM) |
| LT (2) | LT3777842T (OSRAM) |
| MX (1) | MX386987B (OSRAM) |
| NZ (1) | NZ747702A (OSRAM) |
| PL (2) | PL3337462T3 (OSRAM) |
| PT (2) | PT3337462T (OSRAM) |
| RS (2) | RS66471B1 (OSRAM) |
| SG (1) | SG11201903829PA (OSRAM) |
| SI (2) | SI3777842T1 (OSRAM) |
| SM (2) | SMT202500046T1 (OSRAM) |
| TW (1) | TWI787164B (OSRAM) |
| WO (1) | WO2018078429A1 (OSRAM) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220125733A1 (en) * | 2020-10-23 | 2022-04-28 | Atoz Pharmaceuticals Pvt Ltd | Nongranulated compressed tablets of mesalamine, and process of preparation thereof |
| KR20230017814A (ko) * | 2020-10-26 | 2023-02-06 | 일동제약(주) | 옥수수불검화추출물을 포함하는 소형화된 경구투여 제제의 제조방법 및 이에 따라 제조된 소형화 제제 |
| CA3268494A1 (en) | 2022-10-14 | 2024-04-18 | Nestle Sa | DELAYED-RELEASE MELATONIN COMPOSITIONS |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4600723A (en) | 1983-05-18 | 1986-07-15 | Monash University | Method for minimizing disturbances in circadian rhythms of bodily performance and function |
| DE122007000073I1 (de) | 1991-05-09 | 2008-01-31 | Neurim Pharma 1991 | Melatonin enthaltene Arzneimittel |
| EP0565296B1 (en) | 1992-04-07 | 1996-08-07 | Neurim Pharmaceuticals (1991) Limited | Use of melatonin for the manufacture of a medicament for the treatment of benign prostatic hyperplasia |
| US5449683A (en) | 1992-10-01 | 1995-09-12 | Massachussetts Institute Of Technology | Methods of inducing sleep using melatonin |
| WO1995003043A1 (en) * | 1993-07-26 | 1995-02-02 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University | Sustained release oral compositions containing melatonin |
| AT408188B (de) * | 1995-02-01 | 2001-09-25 | Neurim Pharma 1991 | Verwendung von melatonin zur behandlung von an medikamentensucht leidenden patienten |
| US6469044B1 (en) * | 1995-02-01 | 2002-10-22 | Neurim Pharmaceuticals (1991) Ltd. | Method for treating patients suffering from drug dependencies which lead to plasma melationin deficiencies |
| FR2762513B1 (fr) * | 1997-04-23 | 2003-08-22 | Permatec Pharma Ag | Comprimes bioadhesifs |
| WO2000018374A1 (en) | 1998-10-01 | 2000-04-06 | Elan Pharma International, Ltd. | Controlled release nanoparticulate compositions |
| EP1064938A1 (en) * | 1999-06-28 | 2001-01-03 | Sanofi-Synthelabo | Pharmaceutical dosage forms for controlled release producing at least a timed pulse |
| CN1414851A (zh) | 2000-01-05 | 2003-04-30 | 纽里姆药品(1991)有限公司 | 用于治疗对抗高血压药的抗药性和相关病症的方法和制剂 |
| US6458384B2 (en) * | 2000-02-23 | 2002-10-01 | Impetus Ag | Pharmaceutical with predetermined activity profile |
| IL144900A (en) | 2001-08-14 | 2013-12-31 | Neurim Pharma 1991 | Melatonin and drugs containing it for use in the treatment of primary insomnia, and the manufacture of those drugs |
| IL149377A (en) | 2002-04-28 | 2012-10-31 | Neurim Pharma 1991 | Pharmaceutical formulation comprising melatonin for the potentiation of the effect of hypnotic compounds |
| KR20030016215A (ko) * | 2002-07-05 | 2003-02-26 | 뉴림 파머슈티칼스 (1991) 리미티드 | 항고혈압제에 대한 내성 및 관련 질환의 치료를 위한 방법및 제형 |
| AU2004207578B2 (en) * | 2003-01-28 | 2007-06-28 | Collegium Pharmaceutical, Inc. | Multiparticulate compositions of milnacipran for oral administration |
| IL155666A (en) | 2003-04-29 | 2013-12-31 | Neurim Pharma 1991 | Insomnia treatment |
| WO2005063297A2 (en) | 2003-12-24 | 2005-07-14 | Sepracor Inc. | Melatonin combination therapy for improving sleep quality |
| FR2889811B1 (fr) * | 2005-08-19 | 2009-10-09 | Sanofi Aventis Sa | Association d'un agent hypnotique a duree d'action longue et d'un agent hypnotique a duree d'action courte, composition pharmaceutique la contenant et son application en therapeutique. |
| DE102006006532B4 (de) | 2006-02-10 | 2007-11-08 | Biogenerics Pharma Gmbh | Pharmazeutische Zubereitung |
| CN101754753A (zh) | 2007-05-24 | 2010-06-23 | 纽约市哥伦比亚大学托管会 | 褪黑素的持久释放配方 |
| US20100159001A1 (en) * | 2008-12-19 | 2010-06-24 | Cardinal John R | Extended-Release Pharmaceutical Formulations |
| WO2012103411A2 (en) | 2011-01-28 | 2012-08-02 | Zx Pharma, Llc | Controlled-release melatonin composition and related methods |
| US9532952B2 (en) | 2011-01-28 | 2017-01-03 | Physician's Seal, LLC | Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients |
| RU2488388C1 (ru) * | 2012-05-24 | 2013-07-27 | Ооо "Валента Интеллект" | Фармацевтическая композиция для профилактики и лечения психических, поведенческих, когнитивных расстройств |
| ES2677247T3 (es) | 2014-05-28 | 2018-07-31 | Valpharma S.P.A. | Formulación para administración oral que comprende melatonina en forma estable y método de producción de la misma |
-
2016
- 2016-11-29 EP EP20195788.3A patent/EP3777842B1/en active Active
- 2016-11-29 HU HUE16805903A patent/HUE051362T2/hu unknown
- 2016-11-29 CA CA3040027A patent/CA3040027C/en active Active
- 2016-11-29 PL PL16805903T patent/PL3337462T3/pl unknown
- 2016-11-29 KR KR1020187035251A patent/KR102167190B1/ko active Active
- 2016-11-29 CN CN201680090550.4A patent/CN109922795B/zh active Active
- 2016-11-29 ES ES20195788T patent/ES3009413T3/es active Active
- 2016-11-29 SI SI201631888T patent/SI3777842T1/sl unknown
- 2016-11-29 DK DK20195788.3T patent/DK3777842T3/da active
- 2016-11-29 SM SM20250046T patent/SMT202500046T1/it unknown
- 2016-11-29 MX MX2019004736A patent/MX386987B/es unknown
- 2016-11-29 JP JP2019519420A patent/JP6830156B2/ja active Active
- 2016-11-29 WO PCT/IB2016/057190 patent/WO2018078429A1/en not_active Ceased
- 2016-11-29 HR HRP20201722TT patent/HRP20201722T1/hr unknown
- 2016-11-29 HU HUE20195788A patent/HUE070190T2/hu unknown
- 2016-11-29 LT LTEP20195788.3T patent/LT3777842T/lt unknown
- 2016-11-29 FI FIEP20195788.3T patent/FI3777842T3/fi not_active Application Discontinuation
- 2016-11-29 PT PT168059038T patent/PT3337462T/pt unknown
- 2016-11-29 PL PL20195788.3T patent/PL3777842T3/pl unknown
- 2016-11-29 ES ES16805903T patent/ES2828034T3/es active Active
- 2016-11-29 NZ NZ747702A patent/NZ747702A/en active IP Right Revival
- 2016-11-29 LT LTEP16805903.8T patent/LT3337462T/lt unknown
- 2016-11-29 EP EP16805903.8A patent/EP3337462B1/en active Active
- 2016-11-29 SG SG11201903829PA patent/SG11201903829PA/en unknown
- 2016-11-29 HR HRP20250166TT patent/HRP20250166T1/hr unknown
- 2016-11-29 AU AU2016426598A patent/AU2016426598C1/en active Active
- 2016-11-29 RS RS20250094A patent/RS66471B1/sr unknown
- 2016-11-29 SI SI201630947T patent/SI3337462T1/sl unknown
- 2016-11-29 SM SM20200575T patent/SMT202000575T1/it unknown
- 2016-11-29 DK DK16805903.8T patent/DK3337462T3/da active
- 2016-11-29 RS RS20201242A patent/RS61024B1/sr unknown
- 2016-11-29 EP EP24208766.6A patent/EP4474012A3/en active Pending
- 2016-11-29 PT PT201957883T patent/PT3777842T/pt unknown
- 2016-12-26 TW TW105143159A patent/TWI787164B/zh active
-
2018
- 2018-10-24 IL IL262537A patent/IL262537B/en active IP Right Grant
- 2018-10-31 US US16/176,338 patent/US10722494B2/en active Active
-
2019
- 2019-01-24 AU AU2019200479A patent/AU2019200479B2/en active Active
- 2019-11-28 AU AU2019101470A patent/AU2019101470B4/en not_active Expired
-
2020
- 2020-06-16 US US16/902,419 patent/US10869857B2/en active Active
- 2020-10-14 CY CY20201100971T patent/CY1123449T1/el unknown
-
2021
- 2021-01-18 AU AU2021200268A patent/AU2021200268A1/en not_active Abandoned
-
2023
- 2023-03-31 AU AU2023202003A patent/AU2023202003A1/en active Pending
-
2025
- 2025-09-18 AU AU2025234204A patent/AU2025234204A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011509295A5 (OSRAM) | ||
| ES2865278T3 (es) | Amantadina para mejorar la marcha en esclerosis múltiple | |
| JP2009537548A (ja) | ウイルス感染症の治療のための方法および組成物 | |
| JP2017510607A5 (OSRAM) | ||
| JP2021152050A (ja) | フマル酸ジメチルを含む医薬ビーズ製剤 | |
| US11166931B2 (en) | Induction of arteriogenesis with an NO (nitric oxide) donor | |
| JP2019533672A5 (OSRAM) | ||
| JP2016505050A5 (OSRAM) | ||
| KR20090045149A (ko) | 류마티스 질환의 지연-방출형 글루코코르티코이드 치료제 | |
| HRP20201722T1 (hr) | Minitablete melatonina i postupak njihove proizvodnje | |
| JP2011506607A5 (OSRAM) | ||
| HRP20251043T1 (hr) | Novi oralni farmaceutski pripravak i režim doziranja za terapiju progresivnih fibrozirajućih intersticijskih bolesti pluća | |
| US9675552B2 (en) | Use of stabilized granules containing glyceryl trinitrate for arteriogenesis | |
| JP6420923B1 (ja) | 医薬 | |
| JP2018502168A5 (OSRAM) | ||
| CN104906063A (zh) | 一种新型复方安眠控释制剂的释放方式及其制备方法 | |
| RU2013124994A (ru) | КОМБИНАЦИЯ БЕВАЦИЗУМАБА И 2,2-ДИМЕТИЛ-N-((S)-6-ОКСО-6,7-ДИГИДРО-5Н-ДИБЕНЗО[b,d]АЗЕПИН-7-ИЛ)-N'-(2,2,3,3,3-ПЕНТАФТОР-ПРОПИЛ)-МАЛОНАМИДА ДЛЯ ЛЕЧЕНИЯ ПРОЛИФЕРАТИВНЫХ ЗАБОЛЕВАНИЙ | |
| NZ782840B2 (en) | Melatonin mini-tablets and method of manufacturing the same | |
| CN112843053B (zh) | Ns5a抑制剂组合物 | |
| US11759471B2 (en) | Modified release pharmaceutical composition and method for the treatment of mental disorders | |
| FI4065134T3 (fi) | Rautasuksinaatin antaminen suun kautta käytettäväksi raudanpuutoksen hoidossa potilailla, joilla on sydämen vajaatoiminta | |
| Sundaravel et al. | Methylene blue to the rescue in accidental treprostinil overdose | |
| EP2668948A1 (en) | Use of stabilized granules containing glyceryl trinitrate for arteriogenesis | |
| WO2017100324A1 (en) | Combination therapy for treating female hypoactive sexual desire disorders | |
| CN112843013A (zh) | 治疗丙型肝炎的组合物及其制备方法 |